subscribeSubscribe
FDA Confirms Paragraph IV Patent Litigation for Dalbavancin Hydrochloride

FDA Confirms Paragraph IV Patent Litigation for Dalbavancin Hydrochloride
FDA
08 Aug 2023
Share Share
Paladin Labs Launches of Xydalba (dalbavancin for injection) in Canada

Paladin Labs Launches of Xydalba (dalbavancin for injection) in Canada
YAHOO FINANCE
18 Jan 2022
Share Share
Trial of existing antibiotic for treating Staphylococcus aureus bacteremia

Trial of existing antibiotic for treating Staphylococcus aureus bacteremia
NIH
27 Apr 2021
Share Share
Global MRSA Drugs Market to Surpass US$ 1.3 Billion by 2026

Global MRSA Drugs Market to Surpass US$ 1.3 Billion by 2026
BUSINESSWIRE
24 Sep 2019
Share Share
Correvio Highlights FDA Acceptance of United Therapeutics` Trevyent NDA

Correvio Highlights FDA Acceptance of United Therapeutics` Trevyent NDA
BIOSPACE
11 Sep 2019
Share Share
Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer

Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
PRESS RELEASE
04 Jun 2018
Share Share
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
PR NEWSWIRE
15 Apr 2018
Share Share
SMC OKs four new therapies for NHS use in Scotland

SMC OKs four new therapies for NHS use in Scotland
Selina McKee PHARMATIMES
18 Jan 2017
Share Share
UK launch for Cardiome’s skin infections antibiotic

UK launch for Cardiome’s skin infections antibiotic
Selina McKee PHARMATIMES
08 Dec 2016
Share Share
EMA approves Cardiome Pharma`s Xydalba single dose infusion

EMA approves Cardiome Pharma`s Xydalba single dose infusion
PHARMABIZ
10 Aug 2016
Share Share